Details for New Drug Application (NDA): 210045
✉ Email this page to a colleague
NDA 210045 describes CONSENSI, which is a drug marketed by Purple Biotech and is included in one NDA. There are five patents protecting this drug. Additional details are available on the CONSENSI profile page.
The generic ingredient in CONSENSI is amlodipine besylate; celecoxib. There are fifty drug master file entries for this compound. Additional details are available on the amlodipine besylate; celecoxib profile page.
The generic ingredient in CONSENSI is amlodipine besylate; celecoxib. There are fifty drug master file entries for this compound. Additional details are available on the amlodipine besylate; celecoxib profile page.
Summary for 210045
| Tradename: | CONSENSI |
| Applicant: | Purple Biotech |
| Ingredient: | amlodipine besylate; celecoxib |
| Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 210045
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 2.5MG BASE;200MG | ||||
| Approval Date: | May 31, 2018 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Jun 14, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Sign Up | Patent Expiration: | Jun 14, 2038 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Jun 14, 2038 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
